Beyond arterial innovations, we are witnessing a revolution in valve therapies and structural heart medicine. Solutions for the mitral and tricuspid valves are progressing rapidly, while catheter-based aortic valve replacement has become standard practice. 

Heart failure remains one of the most challenging conditions, and new technologies for remote monitoring will be presented at the conference alongside additional advanced treatments. Stroke interventions, catheter-based treatments for cerebral aneurysms, and clot-removal procedures in the brain and lungs are likewise emerging as technologies that are becoming standard in hospitals.

The De-Haan Prize for a groundbreaking innovative company, in the amount of $200,000, will also be awarded this year to the leading contender. Among the competitors are new ultrasound-based technologies for treating hypertension.

AI-enhanced imaging tools enabling broader and more accurate use of ultrasound diagnostics, neuromodulation treatments for atrial fibrillation, a novel lymphatic-drainage therapy for heart failure, and more. Dozens of companies from Israel and around the world are vying for this prestigious award.

Over the years, the ICI Conference has served as the driving engine encouraging physicians and entrepreneurs to think differently, the catalyst accelerating interactions between international corporations and Israeli innovators, and the integrator connecting medicine, entrepreneurship, academia, and industry.

 The results can be seen around the globe. We expect a conference attended by thousands of participants, including hundreds from abroad. Israel will continue to lead the world in breakthrough medical innovation.